Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP767205.RAqNMznBCAPgNnK4y70i4Bdj_2VFJOkvyBX0d-vVfjFjU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP767205.RAqNMznBCAPgNnK4y70i4Bdj_2VFJOkvyBX0d-vVfjFjU130_assertion type Assertion NP767205.RAqNMznBCAPgNnK4y70i4Bdj_2VFJOkvyBX0d-vVfjFjU130_head.
- NP767205.RAqNMznBCAPgNnK4y70i4Bdj_2VFJOkvyBX0d-vVfjFjU130_assertion description "[The invasive breast carcinomas were classified using semiquantitative immunohistochemical results for estrogen receptor (ER), progesterone receptor, (PR), and HER2 into following classes: Luminal A (strong ER+, HER2 negative), Luminal B (weak to moderate ER/PR+, HER2 negative), Triple Negative (TN; ER/PR negative, HER2 negative), ERBB2 (ER/PR negative, HER2 positive), Luminal A-HER2 Hybrid (strong ER+, HER2 positive), Luminal B-HER2 Hybrid (weak to moderate ER/PR+, HER2 positive).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP767205.RAqNMznBCAPgNnK4y70i4Bdj_2VFJOkvyBX0d-vVfjFjU130_provenance.
- NP767205.RAqNMznBCAPgNnK4y70i4Bdj_2VFJOkvyBX0d-vVfjFjU130_assertion evidence source_evidence_literature NP767205.RAqNMznBCAPgNnK4y70i4Bdj_2VFJOkvyBX0d-vVfjFjU130_provenance.
- NP767205.RAqNMznBCAPgNnK4y70i4Bdj_2VFJOkvyBX0d-vVfjFjU130_assertion SIO_000772 19801938 NP767205.RAqNMznBCAPgNnK4y70i4Bdj_2VFJOkvyBX0d-vVfjFjU130_provenance.
- NP767205.RAqNMznBCAPgNnK4y70i4Bdj_2VFJOkvyBX0d-vVfjFjU130_assertion wasDerivedFrom befree-2016 NP767205.RAqNMznBCAPgNnK4y70i4Bdj_2VFJOkvyBX0d-vVfjFjU130_provenance.
- NP767205.RAqNMznBCAPgNnK4y70i4Bdj_2VFJOkvyBX0d-vVfjFjU130_assertion wasGeneratedBy ECO_0000203 NP767205.RAqNMznBCAPgNnK4y70i4Bdj_2VFJOkvyBX0d-vVfjFjU130_provenance.